Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check7 days agoChange DetectedIPD sharing information was added to the study page, including an IPD Sharing URL and plan description. The update also introduces IPD sharing access criteria and related policy language, clarifying the availability of de-identified participant data to qualified researchers.SummaryDifference0.5%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a new build of the platform. There is no visible change to the study details or other content presented to users.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.0 tag. This signals an update to the page's template or content without changing the trial information.SummaryDifference0.0%

- Check57 days agoChange DetectedEnrollment status updated to 'No longer looking for participants', and new help sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment heading was reformatted to 'Intervention/Treatment', and the revision tag updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check64 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating an administrative update to the study record rather than a substantive change to study details.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a small update to the study record metadata on ClinicalTrials.gov.SummaryDifference0.0%

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.